The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases.
 
Thatcher Ross Heumann
No Relationships to Disclose
 
Peter Wu
No Relationships to Disclose
 
Rebecca Ye
No Relationships to Disclose
 
Alexandra Sansosti
No Relationships to Disclose
 
Akram Habibi
No Relationships to Disclose
 
Marc Kryger
No Relationships to Disclose
 
Cameron Beaudreault
Employment - Histogenetics; Histogenetics (I)
 
Kenneth Bernstein
Employment - ProCure (I)
 
Joshua Seth Silverman
Travel, Accommodations, Expenses - Elekta
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; CytomX Therapeutics
Honoraria - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Merck; Moderna Therapeutics; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Jounce Therapeutics; Kirin Pharmaceuticals; Lion Biotechnologies; Merck; Moderna Therapeutics; Nektar; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda Science Foundation; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Merck; Novartis; Roche; Takeda
 
Anna C. Pavlick
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Merck; Novartis; Regeneron; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst); Millennium (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Regeneron; Sanofi/Regeneron
 
Douglas Kondziolka
Research Funding - Brainlab (Inst)
Patents, Royalties, Other Intellectual Property - Intellectual Property Filing
Travel, Accommodations, Expenses - Brainlab